Press Release: Novartis provides update on Phase -2-

https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html.

Accessed July 27, 2022.

12. Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC.

Transl Lung Cancer Res. 2014; 3(4):242-249.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Anja von Treskow Veronique Boissonnas

Novartis External Communications Global Oncology Communications, Solid Tumors

+41 79 392 8697 (mobile) +1 646 872 3153 (mobile)

anja.von_treskow@novartis.com veronique.boissonnas@novartis.com

Julie Masow

Novartis US External Communications

+1 862 579 8456

Julie.masow@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +4 16 132 43809 Alina Levchuk +1 862 778 3372

Isabella Zinck +41 61 324 7188 Parag Mahanti +1 973-876-4912

(END) Dow Jones Newswires

August 15, 2022 01:15 ET (05:15 GMT)